The use of ruxolitinib and baricitinib in our primary macrophage experiments, to inhibit JAK1/2-dependent cytokine receptor signalling, revealed efficient and high-level productive infection, with over 88% of cells becoming infected in some experiments. This evidence concerns the gene JAK1 and infection.